exemestane + sapanisertib

Exemestane + sapanisertib is an investigational oral combination therapy evaluated primarily for the treatment of hormone receptor-positive (HR+)/HER2-negative advanced or metastatic breast cancer in postmenopausal women. Exemestane is a steroidal aromatase inhibitor that suppresses estrogen synthesis, thereby reducing estrogen-driven tumor growth. Sapanisertib is a potent, orally bioavailable small molecule that acts as a dual inhibitor of mTOR kinase complexes 1 and 2 (mTORC1/2), targeting key pathways involved in cell proliferation and survival. The combination has been studied in patients who have progressed on prior endocrine therapies, including everolimus-based regimens. Clinical studies indicate the regimen is generally well tolerated and demonstrates clinical benefit, particularly among patients with prior sensitivity to everolimus[1][3][7].

Brand names

exemestane

Other names

SCC-31SCC31SCC 311567915-38-1UNII-RM15YYQ1CIUNII-RM-15YYQ1CIUNII-RM 15YYQ1CI